Listen

Press releases

Receive e-mail alerts

Internal link ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa
June 12, 2018 at 11:00 AM UTC
Internal link ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference
June 04, 2018 at 11:00 AM UTC
Internal link ProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory Board
May 23, 2018 at 11:00 AM UTC
Internal link ProQR Announces Results for the First Quarter of 2018
May 09, 2018 at 11:00 AM UTC
Internal link ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB
April 30, 2018 at 11:00 AM UTC
Internal link ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO
April 23, 2018 at 11:00 AM UTC
Internal link ProQR Announces Annual Meeting of Shareholders
April 11, 2018 at 11:00 AM UTC
Internal link ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology
April 10, 2018 at 11:00 AM UTC
Internal link ProQR to Present at Two Upcoming Conferences
April 03, 2018 at 11:00 AM UTC
Internal link ProQR to Present at Upcoming Investor Conference
March 05, 2018 at 12:00 PM UTC
Internal link ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update
February 28, 2018 at 12:00 PM UTC
Internal link ProQR Supports Rare Disease Day 2018 and Honors Henri A. Termeer
February 27, 2018 at 12:00 PM UTC
Internal link Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A
February 12, 2018 at 12:00 PM UTC
Internal link ProQR to Present at Upcoming Scientific Meeting and Investor Conference
February 06, 2018 at 12:00 PM UTC
Internal link ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology
January 08, 2018 at 12:00 PM UTC
Internal link ProQR Therapeutics Announces Results for the Third Quarter of 2014
November 24, 2014 at 12:00 PM UTC
Internal link ProQR Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
September 23, 2014 at 05:37 PM UTC
Internal link ProQR Announces Pricing of Initial Public Offering
September 18, 2014 at 12:07 PM UTC

Press releases

Internal link ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa

Internal link ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference

Internal link ProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory Board

Internal link ProQR Announces Results for the First Quarter of 2018

Internal link ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB

Internal link ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO

Internal link ProQR Announces Annual Meeting of Shareholders

Internal link ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology

Internal link ProQR to Present at Two Upcoming Conferences

Internal link ProQR to Present at Upcoming Investor Conference

Internal link ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update

Internal link ProQR Supports Rare Disease Day 2018 and Honors Henri A. Termeer

Internal link Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A

Internal link ProQR to Present at Upcoming Scientific Meeting and Investor Conference

Internal link ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology

Internal link ProQR Therapeutics Announces Results for the Third Quarter of 2014

Internal link ProQR Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Internal link ProQR Announces Pricing of Initial Public Offering